Because neural and mesenchymal stem cells can release large amounts of TGF-β, a cytokine with immosuppressive potential, the anti-glioma immune response may be attenuated, resulting in tumor ‘escape’ from normal immunological surveillance [62], [63]. This evidence concerns the gene TGFB1 and central nervous system cancer.